

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	
Charles M. BUCHANAN et al.	Group Art Unit: 1623
Application No.: 10/601,877) Examiner: L. Maier
Filed: June 24, 2003	Confirmation No.: 1308
For: CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME, AND RELATED MATERIALS)))

REPLY TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is a response to the restriction requirement set forth in the Office Action dated August 11, 2004.

For clarity of the record, it should be noted that claims 1-14 (the invention of Group I) were canceled in the paper entitled "Request for Filing Continuation/Divisional Application Under 37 C.F.R. § 1.53(b)," filed on June 24, 2003. Therefore, they need not be included in the requirement.

This oversight appears to be harmless though, since Applicants are electing the invention of Group II (claims 15-19), drawn to sulfonate derivatives of dihydroxybutane. The election is made with traverse.

MPEP § 803 states that an application may be properly restricted to one or more claimed inventions only if (1) the inventions are independent or distinct as claimed, and (2) there is a serious burden on the Examiner if restriction is not

Attorney's Docket No. <u>008111-155</u> Application No. <u>10/601,877</u>

Page 2

required. Thus, even if appropriate reasons exist for requiring restriction, such a requirement should not be made unless there is an undue burden on the Examiner to examine all the claims in a single application. Here, it would appear that the searches involved for the claims would be coextensive. As such, it is not believed to be a serious burden on the Examiner to examine all the claims.

Accordingly, for at least all of the reasons set forth above, withdrawal of the requirement for restriction is requested.

From the foregoing, further and favorable action in the form of a Notice of Allowance is believed to be next in order, and such action is earnestly solicited.

If the Examiner has any questions concerning this Reply, or the application in general, the Examiner is invited to telephone the undersigned at the number listed below.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: September 16, 2004

Nhat D. Phan

Registration No. 39,581

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

VA 377519_1.DOC



HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Charles M. Buchanan et al.

Application No.: 10/601,877

Filing Date:

June 24, 2003

Group Art Unit: 1623

Examiner: LEIGH C MAIER

Confirmation No.: 1308

Title: CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE

SAME AND RELATED MATERIALS

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

_	٠			
٠.	1	-	٠	

End	losed is a reply for the above-identified patent application.					
X	A Petition for Extension of Time is also enclosed.					
	Terminal Disclaimer(s) and the \$_\$55.00 (2814) \$_\$110.00 (1814) fee per Disclaimer due under 37 C.F.R. \§ 1.20(d) are also enclosed.					
	Also enclosed is/are					
	Small entity status is hereby claimed.					
	Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the \$385.00 (2801) \$770.00 (1801) fee due under 37 C.F.R. § 1.17(e).					
	Applicant(s) requests that any previously unentered after final amendments <u>not</u> be entered. Continued examination is requested based on the enclosed documents identified above.					
	Applicant(s) previously submitted					
	on, for which continued examination is requested.					
	Applicant(s) requests suspension of action by the Office until at least which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.					
	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.					



Attorney Docket No. 008111-155
Application No. 10/601,877

X	No additional claim fee is required.
	An additional claim fee is required, and is calculated as shown below.

AMENDED CLAIMS							
·	No. of Claims	Highest of Clai Previou Paid F	ims usly		Extra Claims	Rate	Additional Fee
Total Claims	8	MINUS	8		. 0	x \$18.00 (1202) =	\$ 0.00
Independent Claims	8	MINUS	8	=	0	x \$86.00 (1201) =	\$ 0.00
If Amendment adds n	nultiple depen	dent claims	, add	١\$	290.00 (1203)		
Total Claim Amendment Fee			\$ 0.00				
Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee			\$ 0.00				
FOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT \$			\$ 0.00				

A check in the amount of	of	_ is enclosed for the fee due.
Charge	to Deposit Acco	ount No. 02-4800.
Charge	to credit card.	Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: September 16. 2004

Nhat D. Pha

Registration No. 39,581